Impact of simplified transcatheter aortic valve implantation approach on procedural and clinical outcomes
Methods: We retrospectively included 517 consecutive symptomatic severe aortic stenosis (AS) patients undergoing TAVI. The procedure is performed under general anesthesia accompanied by TEE and with predilatation in the NSA group. Whereas sedation and local anesthesia, removal of the routine use of transesophageal echocardiography (TEE), skipping the predilatation step in appropriate patients is adopted in SA group.
Results: Among 517 patients, 144 underwent TAVI with SA and 363 with NSA. The NSA group was treated with the most Sapien XT valve (69.4% vs. 92.8; P<0.001). There were no significant differences in post-procedural complications between the groups as defined by the Valve Academic Research Consortium (VARC)-2 criteria. Although there was a trend toward lower mortality at 30-day favoring SA group, this finding did not differ significantly between the groups (0% vs. 2.9%, respectively for SA and NSA groups, P=0.058). However, total cumulative mortality at the end of the follow-up period was found to be significantly reduced in the SA group (7.6% vs. 35.7; P<0.001). The multivariate logistic regression analysis revealed that predilatation, general anesthesia, TEE guidance, and simplified approach were independent predictors of total mortality.
Conclusions: Our study showed that simplified TAVI procedure was safe and was no related to adverse events. Compared to the NSA group, SA-TAVI had statistically significant lower total mortality rates.
1. Cribier A, Eltchaninoff H, Bash A, et al. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation. 2002;106(24):3006-3008. doi: 10.1161/01.cir.0000047200.36165.b8.
2. Kodali SK, Williams MR, Smith CR, kar RR, et al; PARTNER Trial Investigators. Two-year outcomes after transcatheter or surgical aortic-valve replacement. N Engl J Med. 2012;366(18):1686-1695. doi: 10.1056/NEJMoa1200384.
3. Makkar RR, Fontana GP, Jilaihawi H, et al; PARTNER Trial Investigators. Transcatheter aortic-valve replacement for inoperable severe aortic stenosis. N Engl J Med. 2012;366(18):1696-1704. doi: 10.1056/NEJMoa1202277.
4. Popma JJ, Deeb GM, Yakubov SJ, et al; Evolut Low Risk Trial Investigators. Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients. N Engl J Med. 2019;380(18):1706-1715. doi: 10.1056/NEJMoa1816885.
5. Akodad M, Lefèvre T. TAVI: Simplification Is the Ultimate Sophistication. Front Cardiovasc Med. 2018;5:96. doi: 10.3389/fcvm.2018.00096.
6. Pagnesi M, Baldetti L, Del Sole P, et al. Predilatation Prior to Transcatheter Aortic Valve Implantation: Is it Still a Prerequisite? Interv Cardiol. 2017;12(2):116-125. doi: 10.15420/icr.2017:17:2.
7. Selle A, Figulla HR, Ferrari M, et al. Impact of rapid ventricular pacing during TAVI on microvascular tissue perfusion. Clin Res Cardiol. 2014;103(11):902-911. doi: 10.1007/s00392-014-0728-9.
8. Kappetein AP, Head SJ, Généreux P, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. Eur Heart J. 2012;33(19):2403-2418. doi: 10.1093/eurheartj/ehs255.
9. Wood DA, Lauck SB, Cairns JA, et al. The Vancouver 3M (Multidisciplinary, Multimodality, But Minimalist) Clinical Pathway Facilitates Safe Next-Day Discharge Home at Low-, Medium-, and High-Volume Transfemoral Transcatheter Aortic Valve Replacement Centers: The 3M TAVR Study. JACC Cardiovasc Interv. 2019;12(5):459-469. doi: 10.1016/j.jcin.2018.12.020.
10. Martin GP, Sperrin M, Bagur R, et al. Pre-Implantation Balloon Aortic Valvuloplasty and Clinical Outcomes Following Transcatheter Aortic Valve Implantation: A Propensity Score Analysis of the UK Registry. J Am Heart Assoc. 2017;6(2):e004695. doi: 10.1161/JAHA.116.004695.
11. Grube E, Naber C, Abizaid A, et al. Feasibility of transcatheter aortic valve implantation without balloon pre-dilation: a pilot study. JACC Cardiovasc Interv. 2011;4(7):751-757. doi: 10.1016/j.jcin.2011.03.015.
12. Kim WK, Praz F, Blumenstein J, et al. Transfemoral aortic valve implantation of Edwards SAPIEN 3 without predilatation. Catheter Cardiovasc Interv. 2017;89(1):E38-E43. doi: 10.1002/ccd.26464.
13. Chan PH, Mario CD, Moat N. Transcatheter aortic valve implantation without balloon predilatation: not always feasible. Catheter Cardiovasc Interv. 2013;82(2):328-332. doi: 10.1002/ccd.24381.
14. Möllmann H, Kim WK, Kempfert J, et al. Transfemoral aortic valve implantation of Edwards SAPIEN XT without predilatation is feasible. Clin Cardiol. 2014;37(11):667-671. doi: 10.1002/clc.22318.
15. Spaziano M, Sawaya F, Chevalier B, et al. Comparison of Systematic Predilation, Selective Predilation, and Direct Transcatheter Aortic Valve Implantation With the SAPIEN S3 Valve. Can J Cardiol. 2017;33(2):260-268. doi: 10.1016/j.cjca.2016.09.007.
16. Kempfert J, Meyer A, Kim WK, et al. First experience without pre-ballooning in transapical aortic valve implantation: a propensity score-matched analysis. Eur J Cardiothorac Surg. 2015;47(1):31-38; discussion 38. doi: 10.1093/ejcts/ezu097.
17. Schymik G, Rudolph T, Jacobshagen C, et al. Balloon-expandable transfemoral transcatheter aortic valve implantation with or without predilation: findings from the prospective EASE-IT TF multicentre registry. Open Heart. 2019;6(2):e001082. doi: 10.1136/openhrt-2019-001082.
18. Strauch J, Wendt D, Diegeler A, et al. Balloon-expandable transapical transcatheter aortic valve implantation with or without predilation of the aortic valve: results of a multicentre registry. Eur J Cardiothorac Surg. 2018;53(4):771-777. doi: 10.1093/ejcts/ezx397.
19. Bijuklic K, Haselbach T, Witt J, et al. Increased Risk of Cerebral Embolization After Implantation of a Balloon-Expandable Aortic Valve Without Prior Balloon Valvuloplasty. JACC Cardiovasc Interv. 2015;8(12):1608-1613. doi: 10.1016/j.jcin.2015.07.013.
20. Pagnesi M, Jabbour RJ, Latib A, et al. Usefulness of Predilation Before Transcatheter Aortic Valve Implantation. Am J Cardiol. 2016;118(1):107-112. doi: 10.1016/j.amjcard.2016.04.018.
21. Lange P, Greif M, Vogel A, et al. Reduction of pacemaker implantation rates after CoreValve® implantation by moderate predilatation. EuroIntervention. 2014;9(10):1151-1157. doi: 10.4244/EIJV9I10A195.
22. Barbanti M, Gulino S, Costa G, Tamburino C. Optimization and simplification of transcatheter aortic valve implantation therapy. Expert Rev Cardiovasc Ther. 2018;16(4):287-296. doi: 10.1080/14779072.2018.1449644.
23. Fava C, Gamboa P, Caponi G, G.mez C, Salmo F, Guevara E, et al. Minimalist Approach for Percutaneous Aortic Valve Implantation. Rev Argent Cardiol 2019;87(4):265-270. doi: 10.7775/rac.v87.i4.12015.
24. Babaliaros V, Devireddy C, Lerakis S, et al. Comparison of transfemoral transcatheter aortic valve replacement performed in the catheterization laboratory (minimalist approach) versus hybrid operating room (standard approach): outcomes and cost analysis. JACC Cardiovasc Interv. 2014;7(8):898-904. doi: 10.1016/j.jcin.2014.04.005.
25. Lefèvre G, Jégou A, Dambrin G, et al. Comparison of TransFemoral Transcatheter Aortic Valve Replacement Performed With a Minimally Invasive Simplified Technique: "FAST" Versus a Standard Approach. J Invasive Cardiol. 2019;31(10):300-306.
26. Fiorina C, Maffeo D, Curello S, et al. Direct transcatheter aortic valve implantation with self-expandable bioprosthesis: feasibility and safety. Cardiovasc Revasc Med. 2014;15(4):200-203. doi: 10.1016/j.carrev.2014.03.005.
Copyright (c) 2025 The European Research Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Downloads
Article Information
- Article Type Research Article
- Submitted February 21, 2026
- Published September 3, 2025
- Issue Vol. 11 No. 5 (2025)
- Section Research Article
